These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15517116)

  • 1. [Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non-placebo controlled administration in 133 patients].
    Brune A; Metze D; Luger TA; Ständer S
    Hautarzt; 2004 Dec; 55(12):1130-6. PubMed ID: 15517116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases.
    Metze D; Reimann S; Beissert S; Luger T
    J Am Acad Dermatol; 1999 Oct; 41(4):533-9. PubMed ID: 10495371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antipuritic therapy with naltrexone].
    Hautarzt; 2005 Apr; 56(4):312. PubMed ID: 16320411
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study.
    Malekzad F; Arbabi M; Mohtasham N; Toosi P; Jaberian M; Mohajer M; Mohammadi MR; Roodsari MR; Nasiri S
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):948-50. PubMed ID: 19453814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of pruritus with topically applied opiate receptor antagonist.
    Bigliardi PL; Stammer H; Jost G; Rufli T; Büchner S; Bigliardi-Qi M
    J Am Acad Dermatol; 2007 Jun; 56(6):979-88. PubMed ID: 17320241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study.
    Wolfhagen FH; Sternieri E; Hop WC; Vitale G; Bertolotti M; Van Buuren HR
    Gastroenterology; 1997 Oct; 113(4):1264-9. PubMed ID: 9322521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy.
    Neuberger J; Jones EA
    Eur J Gastroenterol Hepatol; 2001 Nov; 13(11):1393-4. PubMed ID: 11692070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review.
    Phan NQ; Bernhard JD; Luger TA; Ständer S
    J Am Acad Dermatol; 2010 Oct; 63(4):680-8. PubMed ID: 20462660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study.
    Terg R; Coronel E; Sordá J; Muñoz AE; Findor J
    J Hepatol; 2002 Dec; 37(6):717-22. PubMed ID: 12445410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naltrexone: a case report of pruritus from an antipruritic.
    Sullivan JR; Watson A
    Australas J Dermatol; 1997 Nov; 38(4):196-8. PubMed ID: 9431714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous opioids, mu-opiate receptors and chloroquine-induced pruritus: a double-blind comparison of naltrexone and promethazine in patients with malaria fever who have an established history of generalized chloroquine-induced itching.
    Ajayi AA; Kolawole BA; Udoh SJ
    Int J Dermatol; 2004 Dec; 43(12):972-7. PubMed ID: 15569037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis.
    Jones EA; Dekker LR
    Gastroenterology; 2000 Feb; 118(2):431-2. PubMed ID: 10648471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, vehicle-controlled crossover study to determine the anti-pruritic efficacy, safety and local dermal tolerability of a topical formulation (srd174 cream) of the long-acting opiod antagonist nalmefene in subjects with atopic dermatitis.
    Herzog JL; Solomon JA; Draelos Z; Fleischer A; Stough D; Wolf DI; Abramovits W; Werschler W; Green E; Duffy M; Rothaul A; Tansley R
    J Drugs Dermatol; 2011 Aug; 10(8):853-60. PubMed ID: 21818506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opiate and H1 antagonist effects on histamine induced pruritus and alloknesis.
    Heyer G; Dotzer M; Diepgen LT; Handwerker OH
    Pain; 1997 Nov; 73(2):239-243. PubMed ID: 9415511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The uses of naltrexone in dermatologic conditions.
    Lee B; Elston DM
    J Am Acad Dermatol; 2019 Jun; 80(6):1746-1752. PubMed ID: 30582992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of Naltrexone Treatment for Chronic Inflammatory Dermatologic Conditions: A Systematic Review.
    Ekelem C; Juhasz M; Khera P; Mesinkovska NA
    JAMA Dermatol; 2019 Feb; 155(2):229-236. PubMed ID: 30484835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective treatment of pruritus with naltrexone, an orally active opiate antagonist.
    Metze D; Reimann S; Luger TA
    Ann N Y Acad Sci; 1999 Oct; 885():430-2. PubMed ID: 10816681
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of refractory vulvovaginal pruritus with naltrexone, a specific opiate antagonist.
    Böttcher B; Wildt L
    Eur J Obstet Gynecol Reprod Biol; 2014 Mar; 174():115-6. PubMed ID: 24388844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis.
    Bergasa NV; Schmitt JM; Talbot TL; Alling DW; Swain MG; Turner ML; Jenkins JB; Jones EA
    Hepatology; 1998 Mar; 27(3):679-84. PubMed ID: 9500694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study.
    Bergasa NV; Alling DW; Talbot TL; Wells MC; Jones EA
    J Am Acad Dermatol; 1999 Sep; 41(3 Pt 1):431-4. PubMed ID: 10459118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.